An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

This study is exploring whether re-using an immunotherapy drug called tislelizumab — combined with chemotherapy — can work as a second-line treatment in people with advanced non-small cell lung cancer (NSCLC) whose cancer did not respond well enough to first-line immunotherapy alone. The patients eligible do not have certain driver gene mutations like EGFR or ALK. **You may be eligible if...** - You are 18 or older - You have been diagnosed with Stage IV NSCLC (without bone metastases), confirmed by tissue testing - Your tumor does not have EGFR, ALK, or ROS1 mutations (or relevant targeted therapies are not available) - You previously received immunotherapy (a checkpoint inhibitor) as first-line treatment and had benefit for at least 3 months - You have at least one measurable tumor **You may NOT be eligible if...** - You have never received first-line immunotherapy - Your cancer progressed within 3 months of starting immunotherapy - You have received prior chemotherapy for this cancer - Your general health is too poor to tolerate additional treatment Talk to your doctor to see if this trial is right for you.